BioMed Realty Trust To Report 2012 Third Quarter Results
SAN DIEGO, Oct. 22, 2012 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced it will report results for its third quarter ended September 30, 2012 after the market closes on Thursday, November 1, 2012.
Alan D. Gold, Chairman and Chief Executive Officer, Kent Griffin, President, Matt McDevitt, Executive Vice President, and Greg N. Lubushkin, Chief Financial Officer, will host an investor conference call at 10:00 a.m. Pacific Time on Friday, November 2, 2012 to discuss the company's financial results and operations for the quarter.
The call will be open to all interested investors either through a live audio web cast at the Investor Relations section of the company's web site at www.biomedrealty.com and at www.earnings.com, which will include an online slide presentation to accompany the call, or live by calling (866) 638-3013 (domestic) or (630) 691-2761 (international) with call ID number 33615224. The complete webcast will be archived for 30 days on both web sites. A telephone playback of the conference call will also be available from 12:30 p.m. Pacific Time on Friday, November 2, 2012 until midnight Pacific Time on Wednesday, November 7, 2012 by calling (888) 843-7419 (domestic) or (630) 652-3042 (international) and using access code 33615224#.
About BioMed Realty Trust
BioMed Realty is a company dedicated to delivering the optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 13.1 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Francisco, San Diego, Maryland, New York/New Jersey, Pennsylvania and Seattle, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.
SOURCE BioMed Realty Trust, Inc.